Last reviewed · How we verify
APL-130277
APL-130277 is a Dopamine agonist Small molecule drug developed by Sumitomo Pharma America, Inc.. It is currently in Phase 3 development for Parkinson's disease, acute OFF episodes. Also known as: Apomorphine Hydrochloride, Sublingual Thin Film, amomorphine, Apomorphine Hydrochloride.
APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease.
APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease. Used for Parkinson's disease, acute OFF episodes.
At a glance
| Generic name | APL-130277 |
|---|---|
| Also known as | Apomorphine Hydrochloride, Sublingual Thin Film, amomorphine, Apomorphine Hydrochloride |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Dopamine agonist |
| Target | Dopamine receptors (D1, D2) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
APL-130277 is a small-molecule dopamine agonist administered via subcutaneous injection. It crosses the blood-brain barrier and stimulates dopamine receptors, particularly D1 and D2 receptors, to restore dopaminergic neurotransmission in the basal ganglia. This mechanism provides rapid onset of action for acute motor symptom management in Parkinson's disease patients experiencing OFF episodes.
Approved indications
- Parkinson's disease, acute OFF episodes
Common side effects
- Nausea
- Injection site reactions
- Yawning
- Dizziness
- Somnolence
Key clinical trials
- Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life
- Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain (NA)
- SAD Study in Patients With Parkinson's Disease and Motor Fluctuations (PHASE1)
- Clinical Trial of Intranasal Delivery of NT-301 (PHASE1)
- Blinking and Yawning in Epilepsy: The Role of Dopamine (NA)
- Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease
- SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
- Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APL-130277 CI brief — competitive landscape report
- APL-130277 updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI
Frequently asked questions about APL-130277
What is APL-130277?
How does APL-130277 work?
What is APL-130277 used for?
Who makes APL-130277?
Is APL-130277 also known as anything else?
What drug class is APL-130277 in?
What development phase is APL-130277 in?
What are the side effects of APL-130277?
What does APL-130277 target?
Related
- Drug class: All Dopamine agonist drugs
- Target: All drugs targeting Dopamine receptors (D1, D2)
- Manufacturer: Sumitomo Pharma America, Inc. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease, acute OFF episodes
- Also known as: Apomorphine Hydrochloride, Sublingual Thin Film, amomorphine, Apomorphine Hydrochloride
- Compare: APL-130277 vs similar drugs
- Pricing: APL-130277 cost, discount & access